IKF Pneumologie GmbH & Co. KG — Clinical Trial Site

63 Registered trials

27 Currently recruiting

Organisation

IKF Pneumologie GmbH & Co. KG

Location

Frankfurt Am Main, Germany

Identifier

ORG-100046278

Address

Stresemannallee 3, Sachsenhausen, 60596, Germany

Departments

-
#2604
2602: Pulmonology
2604: Helix Medical Excellence Center Mainz
2605:Institut für klinische Forschung Pneumologie
2606: Institut für klinische Forschung
276001:Pulmonology
276003:Institut für klinische Forschung Pneumologie
2nd Floor
4501: Institut für klinische Forschung Pneumologie
4518: Pulmonology
Clinical Research Center Respiratory Diseases
Clinical Research Centre Respiratory Diseases
Clinical Research Centre, Respiratory Medicine, Helix Medical Excellence Center
DE007: Pulmonology
Helix Medical Excellence Center Mainz
IKF Institut für Klinische Forschung Mainz
IKF Pneumologie GmbH & Co. KG
IKF Pneumologie GmbH & Co. KG (#1)
IKF Pneumologie Mainz
Institut für klinische Forschung Pneumologie
Institut für Klinische Forschung Pneumologie Frankfurt
Institut für klinische Forschung Pneumologie, Clinical Research Center Respiratory Diseases
Interdisziplinaeres Facharztentrum Sachsenhausen
Interdisziplinäres Facharztzentrum
Interdisziplinäres Facharztzentrum Sachsenhausen
lnstitut fuer klinische Forschung Pneumologie
N/A
N/A - Additional streetname as site is located at a corner: Stresemannallee 3
NA
Not applicable
Pneumologie
Pneumology
Pulmonology, Endocrinology, Cardiovascular Diseases

Clinical trials at this site (63)

Search interface

"Efficacy and Safety of Tozorakimab in Symptomatic Chronic Obstructive Pulmonary Disease (COPD) with a History of Exacerbations (MIRANDA)" Ended

2023-505543-39-00 Chronic Obstructive Pulmonary Disease (COPD) 5 2024-02-12
A 12-week double-blind, multicentre, randomised, active-controlled, 2-arm, parallel-group clinical trial to evaluate the safety of CHF5993 p… Ended

2023-503333-22-00 Moderate to severe controlled asthma according to Step 5 2024-01-15
A Randomized, Double-Blind, Placebo-Controlled, Parallel, 4-Arm Dose Ranging Study of the Safety and Efficacy of Nalbuphine Extended-Release… Ended

2023-505296-72-00 Idiopathic Pulmonary Fibrosis (IPF) 4 2023-12-12
Efficacy and safety of Tanimilast in Asthmatics uNcontrolled on ICS-containinG backgrOund maintenance therapy Ended

2022-502208-64-00 Asthma 4 2023-11-25
A Study to Investigate MBS2320 Patients with IPF Ended

2023-504418-30-00 Idiopathic Pulmonary Fibrosis 4 2023-10-24
A Study to Evaluate the Effect of BGF MDI, BFF MDI and Placebo MDI on Exercise Parameters in Participants with COPD Ended

2022-502274-16-00 Chronic Obstructive Pulmonary Disease 11 2023-10-19
A study to evaluate the efficacy and safety of Bemnifosbuvir in High-Risk Outpatients with COVID-19 Ended

2023-504540-33-00 COVID-19 5 2023-03-06
A Study to Evaluate the Efficacy and Safety of Astegolimab in Patients With Chronic Obstructive Pulmonary Disease (COPD) Ended

2023-507093-40-00 Chronic Obstructive Pulmonary Disease (COPD) 4 2022-01-27
A study of GSK3511294 (Depemokimab) in participants who were previously enrolled in 206713 or 213744; Open-Label Extension Ended

2023-505203-23-01 Severe asthma with an eosinophilic phenotype 5 2021-07-26
The efficacy and safety of two doses of CHF6001 DPI as add-on to maintenance COPD triple therapy Ended

2023-510174-13-00 Chronic Obstructive Pulmonary Disease (COPD) 5 2021-06-17
The efficacy and the safety of two doses of CHF6001 for the treatment of Chronic Obstructive Pulmonary Disease (COPD) Ended

2023-510175-60-00 Chronic obstructive pulmonary disease (COPD) and Chron 5 2021-06-16
Non-inferiority study of GSK3511294 (depemokimab) compared with mepolizumab or benralizumab in participants with severe asthma with an eosin… Ended

2023-510230-84-00 Severe asthma with an eosinophilic phenotype 5 2021-05-28
A Variable Length Study to Evaluate the Efficacy and Safety of Budesonide/Glycopyrronium/Formoterol inhaler in Adults and Adolescents with S… Ended

2023-505786-88-00 Severe and inadequately controlled asthma 5 2021-04-25
Study to assess the efficacy, safety, and tolerability of SAR440340/REGN3500/itepekimab in chronic obstructive pulmonary disease (COPD) (AER… Ended

2024-512012-21-00 Chronic Obstructive Pulmonary Disease 5 2021-04-08
A double-blind, placebo-controlled, parallel-group study to evaluate the safety and efficacy of briquilimab in participants with allergic a… Ended

2024-516164-28-00 allergic asthma 3